Lumiradx Limited Stock Fair Value Calculation – LumiraDx Limited to Sell Point of Care Technology Platform to Roche
December 30, 2023
☀️Trending News
LUMIRADX ($NASDAQ:LMDX): LumiraDx Limited, a medical diagnostics company, has recently announced that it has reached an agreement with Roche, a healthcare company, to sell its point of care technology platform. This platform is designed to provide rapid, near-patient results to support accurate diagnosis and treatment decisions. The acquisition is expected to strengthen Roche’s diagnostics business, allowing for improved patient care. The LumiraDx Limited is a publicly traded medical diagnostics company, based in the United Kingdom, and devoted to developing and delivering innovative point-of-care diagnostic solutions. It is focused on the development of innovative products that improve the efficiency of healthcare delivery, providing clinicians with rapid test results at the point of care. The company’s product portfolio includes a range of rapid tests for infectious diseases, including respiratory infections, gastrointestinal diseases, and sexually transmitted infections. Additionally, LumiraDx has developed a handheld device that allows for the detection of multiple diseases without the need for laboratory testing. This device is designed to facilitate faster diagnosis and enable more accurate treatment decisions. With the acquisition of LumiraDx’s point of care technology platform, Roche will be able to improve its diagnostics business while delivering more reliable and timely patient care. The point of care technology platform will also provide Roche with access to LumiraDx’s portfolio of rapid tests, allowing for quicker diagnosis and treatment decisions.
In addition, Roche can expand its capabilities in the areas of infectious disease diagnostics and handheld devices, further strengthening its position in the healthcare sector.
Stock Price
LUMIRADX LIMITED announced on Friday that it had reached an agreement to sell its point of care technology platform to Roche. The stock opened at $0.1 and closed at the same price, a 2.2% decrease from the previous closing price. This marks a significant milestone for the company as it provides them with the potential to rapidly expand their reach and make use of Roche’s extensive resources. This move is seen by many as a strategic way to position LUMIRADX LIMITED for further success.
It will also allow them to bring their product to more people and provide quality healthcare solutions. It is expected that the acquisition will have a positive impact on both companies, helping them to reach their respective goals. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Lumiradx Limited. More…
| Total Revenues | Net Income | Net Margin |
| 126.52 | -338.03 | -225.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Lumiradx Limited. More…
| Operations | Investing | Financing |
| -129.66 | -10.81 | 58.1 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Lumiradx Limited. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 340.83 | 555.55 | -0.67 |
Key Ratios Snapshot
Some of the financial key ratios for Lumiradx Limited are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 122.4% | – | -278.2% |
| FCF Margin | ROE | ROA |
| -111.0% | 119.5% | -64.5% |
Analysis – Lumiradx Limited Stock Fair Value Calculation
At GoodWhale, we have conducted a thorough analysis of LUMIRADX LIMITED‘s fundamentals and have come to the conclusion that the company’s fair value is around $0.9 per share. Our proprietary Valuation Line has been instrumental in arriving at this conclusion. Currently, LUMIRADX LIMITED stock is being traded at a price of $0.1 per share, which is significantly lower than its fair value. This depicts that the stock is currently undervalued by a massive 88.6%. We believe that this presents a great opportunity for investors who are looking to make a prudent investment in the near future. More…
Peers
It is a major player in the healthcare industry, competing with other major players such as ConvaTec Group PLC, Rainbow Childrens Medicare Ltd, and Radius Residential Care Ltd. These companies offer a range of products and services to meet the needs of the healthcare industry, and it is up to LumiraDx Ltd to stay competitive in order to maintain its position.
– ConvaTec Group PLC ($LSE:CTEC)
ConvaTec Group PLC is a global medical technology company that develops, manufactures, and markets innovative medical products and services for wound care, ostomy care, continence and critical care, and infusion devices. The company has an impressive market capitalization of 4.77B as of 2023 and a Return on Equity of 4.96%, indicating its strong financial performance. The high market cap reflects investor confidence in the company’s ability to deliver consistent returns on investments and its long-term potential. Furthermore, the company’s impressive ROE indicates that it has been able to generate profits from its total shareholder equity.
– Rainbow Childrens Medicare Ltd ($BSE:543524)
Rainbow Childrens Medicare Ltd is a healthcare company that provides quality medical services to children. The company has a market capitalization of 72.75B as of 2023, and its Return on Equity (ROE) is 26.79%. This indicates that for every dollar of equity invested in the business, it generates 26.79 cents of earnings. Rainbow Childrens Medicare Ltd has a strong balance sheet and is well-positioned to take advantage of growth opportunities in the healthcare sector. The company is committed to providing quality healthcare services to its customers and strives to remain the leader in the industry.
– Radius Residential Care Ltd ($NZSE:RAD)
Radius Residential Care Ltd is a leading provider of residential care services for individuals and families in the United Kingdom. With a market cap of 88.22M as of 2023, the company has shown strong growth in terms of its market capitalization. The company has also achieved a strong return on equity (ROE) of 11.56%, indicating that the company is generating value for its shareholders. Radius Residential Care Ltd is committed to offering quality care and support to the people that rely on their services and continues to strive for excellence in the care industry.
Summary
LumiraDx Limited is an innovative healthcare technology company that has recently agreed to sell its point of care technology platform to Roche. This represents a great business opportunity for investors, as LumiraDx provides a range of cutting-edge solutions to healthcare providers and develops products with the latest advances in medical technology.
In addition, the company focuses on providing cost-effective care solutions that will enable healthcare providers to provide better care and reduce costs. As such, the sale of its platform to Roche should prove to be a sound investment decision. Investors should consider LumiraDx as a potential long-term investment option as the company continues to develop and refine its products and services.
